Treatment of Polymyalgia Rheumatica: Lower Initial Dose

Catoggio, Luís J.; Soriano, Enrique R.; Imamura, Patricia M.

doi:10.1093/rheumatology/30.5.393-a

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also identified seven retrospective studies with comparisons between >7.5 mg/day and ≤7.5 mg/day,9 20 26 >15 mg/day and ≤15 mg/day12 24–26 and >30 mg/day and ≤30 mg/day oral prednisone 18 26…”

Section: Resultsmentioning

confidence: 99%

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

et al. 2015

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

et al. 2015

View full text Add to dashboard Cite

“…Ultrasonography has been proposed as an adjunct to the diagnosis of polymyalgia rheumatica. 10 Ultrasound shows characteristic pathological findings of the shoulders and hips that can help distinguish polymyalgia rheumatica from other diseases. Typical findings on ultrasound include subdeltoid bursitis and biceps tendon tenosynovitis of the shoulders and, less frequently, synovitis of the glenohumeral joint.…”

Section: Sources and Selection Criteriamentioning

confidence: 99%

Polymyalgia rheumatica

Michet

Matteson

2008

BMJ

View full text Add to dashboard Cite

“…There are a few local reports about PMR treatment. Catoggio et al 32 suggested that PMR can be controlled in most cases with lower doses without relapses within the first few months if the rate of reduction is slow. Polymyalgia rheumatica remission seems to be achieved with prednisone treatment at an initial dose of 16 mg/d in most patients.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Relapse and/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica

Vinicki

Gut

Maliandi³

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

BackgroundIn polymyalgia rheumatica (PMR) relapses and long-term GC dependency are common. We assessed risk factors for higher relapse rate and/or prolonged glucocorticoid therapy in PMR patients.MethodsA multicenter and observational study (chart review) of PMR patients seen between 2006 and 2021 who had at least a 3-month follow-up period after starting GCs was performed. Results were expressed as median and interquartile range 25th–75th or mean ± standard deviation for numerical variables and percentage for categorical ones. Relapse versus nonrelapse groups were compared using Cox proportional analysis. Hazards ratios (HRs) with 95% confidence intervals (CIs) are reported. In all cases, a p value <0.05 was considered to indicate statistical significance.ResultsWe included 185 patients (69.1% female). The median follow-up time was 17.1 months (interquartile range, 6.8–34.7). Incidence of relapses was 1.2 per 100 persons/month. In univariate analysis, PMR patients with a previous history of dyslipidemia had a lower risk of relapse (HR, 0.55; 95% CI, 0.33–0.94; p = 0.03); high-dose GC (HR, 2.35; 95% CI, 1.42–3.87; p = 0.001) and faster GC dose reduction had higher risk of relapse (HR, 3.04; 95% CI, 1.77–5.21; p = 0.001). In multivariate analysis, a previous history of dyslipidemia had a lower risk of relapse (HR, 0.54; 95% CI, 0.32–0.92; p = 0.023), and high dose of GC (HR, 2.46; 95% CI, 1.49–4.08; p = 0.001) remained the only risk factors for relapse.ConclusionsLower doses of corticosteroids and a slow rate of reduction are critical to avoid relapse in PMR. Risk factors for higher relapse rate rely on therapy more than clinical characteristics of the patients at the time of diagnosis of PMR.

show abstract

Treatment of Polymyalgia Rheumatica: Lower Initial Dose

Cited by 10 publications

References 0 publications

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

Polymyalgia rheumatica

Risk Factors for Relapse and/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica

Contact Info

Product

Resources

About